Details of the Drug

General Information of Drug (ID: DMYLDN9)

Drug Name

Cudetaxestat

Synonyms

Cudetaxestat; BLD-0409; PAT-409; 6B7TYB2MJX; 1782070-21-6; UNII-6B7TYB2MJX; 3-((2,6-Dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid; Benzoic acid, 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluoro-; CUDETAXESTAT [INN]; CHEMBL4802146; SCHEMBL16739453; BDBM555280; GLXC-26831; EX-A6053; Cudetaxestat (Synonyms: BLD-0409); US11344533, Compound 1-13; MS-28961; HY-145561; CS-0376048; 3-{[2,6-dichloro-7-fluoro-1-(1-propylpyrazol-4-yl)indol-3-yl]sulfanyl}-2-fluorobenzoic acid; Synthesis of 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H15Cl2F2N3O2S
Canonical SMILES: CCCN1C=C(C=N1)N2C3=C(C=CC(=C3F)Cl)C(=C2Cl)SC4=CC=CC(=C4F)C(=O)O
InChI: InChI=1S/C21H15Cl2F2N3O2S/c1-2-8-27-10-11(9-26-27)28-18-13(6-7-14(22)17(18)25)19(20(28)23)31-15-5-3-4-12(16(15)24)21(29)30/h3-7,9-10H,2,8H2,1H3,(H,29,30)
InChIKey: NMDFAQXLJQRHMS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 91809202
TTD ID: DN9V3S

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular lysophospholipase D (E-NPP2)	TTSCIM2	ENPP2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05373914) RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health.
2	An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021 May;31(5):421-434.